Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

V. Craig Jordan

Virgil Craig Jordan is Dallas/Ft. Worth Living Legend Chair of Cancer Research, Professor of Breast Medical Oncology, Professor of Molecular and Cellular Oncology, Chief, Section of Basic Science Research and Pharmacology, University of Texas MD Anderson Cancer Center, 1500 Holcombe Blvd. Unit #1354, Houston, TX 77030, United States.

Contact Info

Email:
VCJordan@mdanderson.org

Recent stories

  • Chemoprevention in British women is inadequateSubscription

    31 MAR 2017

    We write to outline our concerns that breast cancer prevention strategies are not being implemented to their fullest potential in the UK. Breast cancer is the most common female cancer and the second leading cause of death in women in the UK. According to Cancer Research UK, there were more than 55,000 new cases of breast cancer and more than 11,000 deaths from breast cancer in 2014

  • Breast cancer prevention trumps cureSubscription

    23 DEC 2016

    Breast cancer is the most prevalent female cancer and is estimated to increase by 50% by 2030 compared to the incidence in 2011. The decision by the National Institute for Health and Care Excellence (NICE), the UK health technology appraiser, to recommend the use of preventive medicines, which are known to decrease the risk of developing breast cancer, is a welcome advance in public health. These medicines have been rigorously studied, and tens of thousands of women who at high risk of

  • 3D MRI scan of a breast with breast cancer

    Improving long-term adjuvant anti-oestrogenic therapy for breast cancerSubscription

    8 JUN 2016

    Long-term (five years) adjuvant tamoxifen treatment for oestrogen receptor-positive, or ER-positive, breast cancer post-surgery is recognised as a major advance in healthcare. Clinical trials comparing standard and extended tamoxifen therapy found a major decrease in mortality occurred in the ten years following a decade of adjuvant therapy. Studies in premenopausal breast cancer patients showed that ovarian function suppression (OFS) plus an aromatase inhibitor (AI), such as

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.